Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk.
Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured), who was unanimously elected as its new chairman.
He succeeds Dr Peter Fellner – who has served as chairman since 2013 but resigned with immediate effect shortly after the company turned down Novo’s unsolicited offer.
Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.
Dr Edwin Moses, chief executive officer at Ablynx, said: “We are very fortunate to have an extremely suitable successor with Bo Jesper, allowing for an orderly transition at this important time.
“Hensen is the ideal person to lead the board moving forward and his wealth of experience is particularly relevant as we advance towards the potential approvals and global launches of our lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”
Source: PM Live
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).